299 related articles for article (PubMed ID: 15563548)
21. Downregulation of the GHRH/GH/IGF1 axis in a mouse model of Börjeson-Forssman-Lehman syndrome.
McRae HM; Eccles S; Whitehead L; Alexander WS; Gécz J; Thomas T; Voss AK
Development; 2020 Oct; 147(21):. PubMed ID: 32994169
[TBL] [Abstract][Full Text] [Related]
22. Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1.
Dobie R; Ahmed SF; Staines KA; Pass C; Jasim S; MacRae VE; Farquharson C
J Cell Physiol; 2015 Nov; 230(11):2796-806. PubMed ID: 25833299
[TBL] [Abstract][Full Text] [Related]
23. 17β-Estradiol positively modulates growth hormone signaling through the reduction of SOCS2 negative feedback in human osteoblasts.
Bolamperti S; Mrak E; Moro G; Sirtori P; Fraschini G; Guidobono F; Rubinacci A; Villa I
Bone; 2013 Jul; 55(1):84-92. PubMed ID: 23567159
[TBL] [Abstract][Full Text] [Related]
24. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b).
Greenhalgh CJ; Bertolino P; Asa SL; Metcalf D; Corbin JE; Adams TE; Davey HW; Nicola NA; Hilton DJ; Alexander WS
Mol Endocrinol; 2002 Jun; 16(6):1394-406. PubMed ID: 12040024
[TBL] [Abstract][Full Text] [Related]
25. Potential role of growth hormone in impairment of insulin signaling in skeletal muscle, adipose tissue, and liver of rats chronically treated with arginine.
de Castro Barbosa T; de Carvalho JE; Poyares LL; Bordin S; Machado UF; Nunes MT
Endocrinology; 2009 May; 150(5):2080-6. PubMed ID: 19106217
[TBL] [Abstract][Full Text] [Related]
26. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor of intestinal epithelial cell proliferation.
Miller ME; Michaylira CZ; Simmons JG; Ney DM; Dahly EM; Heath JK; Lund PK
Gastroenterology; 2004 Aug; 127(2):570-81. PubMed ID: 15300589
[TBL] [Abstract][Full Text] [Related]
27. The somatotropic axis during the physiological estrus cycle in dairy heifers--Effect on hepatic expression of GHR and SOCS2.
Mense K; Meyerholz M; Gil Araujo M; Lietzau M; Knaack H; Wrenzycki C; Hoedemaker M; Piechotta M
J Dairy Sci; 2015 Apr; 98(4):2409-18. PubMed ID: 25704974
[TBL] [Abstract][Full Text] [Related]
28. Type II SOCS as a feedback repressor for GH-induced Igf1 expression in carp hepatocytes.
Jiang X; Xiao J; He M; Ma A; Wong AO
J Endocrinol; 2016 May; 229(2):171-86. PubMed ID: 27271287
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver.
Tateno C; Kataoka M; Utoh R; Tachibana A; Itamoto T; Asahara T; Miya F; Tsunoda T; Yoshizato K
Endocrinology; 2011 Apr; 152(4):1479-91. PubMed ID: 21303949
[TBL] [Abstract][Full Text] [Related]
30. Reduced bone mineral density in SOCS-2-deficient mice.
Lorentzon M; Greenhalgh CJ; Mohan S; Alexander WS; Ohlsson C
Pediatr Res; 2005 Feb; 57(2):223-6. PubMed ID: 15585682
[TBL] [Abstract][Full Text] [Related]
31. Analysis of neuronal subpopulations in mice over-expressing suppressor of cytokine signaling-2.
Ransome MI; Turnley AM
Neuroscience; 2005; 132(3):673-87. PubMed ID: 15837129
[TBL] [Abstract][Full Text] [Related]
32. Suppressor of cytokine signaling 2 (
Dobie R; MacRae VE; Pass C; Milne EM; Ahmed SF; Farquharson C
Dis Model Mech; 2018 Jan; 11(1):. PubMed ID: 29343614
[TBL] [Abstract][Full Text] [Related]
33. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.
Sjögren K; Jansson JO; Isaksson OG; Ohlsson C
Minerva Endocrinol; 2002 Dec; 27(4):299-311. PubMed ID: 12511852
[TBL] [Abstract][Full Text] [Related]
34. Reduction of adiposity with prolonged growth hormone treatment in old obese rats: effects on glucose handling and early insulin signaling.
Johansen T; Laurino C; Barreca A; Malmlöf K
Growth Horm IGF Res; 2005 Feb; 15(1):55-63. PubMed ID: 15701573
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of CNS populations in knockout mice with altered growth hormone responsiveness.
Ransome MI; Goldshmit Y; Bartlett PF; Waters MJ; Turnley AM
Eur J Neurosci; 2004 Apr; 19(8):2069-79. PubMed ID: 15090034
[TBL] [Abstract][Full Text] [Related]
36. SOCS2 is the critical regulator of GH action in murine growth plate chondrogenesis.
Pass C; MacRae VE; Huesa C; Faisal Ahmed S; Farquharson C
J Bone Miner Res; 2012 May; 27(5):1055-66. PubMed ID: 22228213
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated.
Näntö-Salonen K; Muller HL; Hoffman AR; Vu TH; Rosenfeld RG
Endocrinology; 1993 Feb; 132(2):781-8. PubMed ID: 7678799
[TBL] [Abstract][Full Text] [Related]
38. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo.
Michaylira CZ; Simmons JG; Ramocki NM; Scull BP; McNaughton KK; Fuller CR; Lund PK
Am J Physiol Gastrointest Liver Physiol; 2006 Sep; 291(3):G472-81. PubMed ID: 16574995
[TBL] [Abstract][Full Text] [Related]
39. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces suppressor of cytokine signaling 2 in murine B cells.
Boverhof DR; Tam E; Harney AS; Crawford RB; Kaminski NE; Zacharewski TR
Mol Pharmacol; 2004 Dec; 66(6):1662-70. PubMed ID: 15371557
[TBL] [Abstract][Full Text] [Related]
40. Suppressor of cytokine signaling 2 (SOCS2) deletion protects against multiple low dose streptozotocin-induced type 1 diabetes in adult male mice.
Alkharusi A; Mirecki-Garrido M; Ma Z; Zadjali F; Flores-Morales A; Nyström T; Castrillo A; Bjorklund A; Norstedt G; Fernandez-Pérez L
Horm Mol Biol Clin Investig; 2016 Apr; 26(1):67-76. PubMed ID: 26562042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
